Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervica...Подробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

The OncoAlert Colloquium Day 3 Breast CancerПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

The OncoAlert Colloquium Day 3 Breast CancerПодробнее

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...Подробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020Подробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

What's New and on the Horizon for Metastatic Breast Cancer?Подробнее

Targeting the PI3K Pathway in the Therapy of Breast Cancer - by Jose Baselga, MD, PhDПодробнее

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, TargetsПодробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

Phase III KATHERINE Clinical TrialПодробнее

Advances in HER2-positive and HER2-low Breast CancerПодробнее